Dasatinib inhibits the proliferation and function of CD4 +CD25+ regulatory T cells

British Journal of Haematology

Volumn 144, Issue 2, 2009, Pages 195-205

  Fei, Fei ^a   Yu, Yingzhe ^a   Schmitt, Anita ^a   Rojewski, Markus Thomas ^a   Chen, Baoan ^b   Götz, Marlies ^a   Döhner, Hartmut ^a   Bunjes, Donald ^a   Schmitt, Michael ^a  

^a UNIVERSITY OF ULM   (Germany)

^b SOUTHEAST UNIVERSITY   (China)

Author keywords

CD4+CD25+ regulatory T cells; Dasatinib; Signal transduction; T cells; Tyrosine kinase inhibitor

Indexed keywords

CYTOTOXIC T LYMPHOCYTE ANTIGEN 4; DASATINIB; GLUCOCORTICOID INDUCED TUMOR NECROSIS FACTOR RECEPTOR; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; SCAVENGER RECEPTOR C; TRANSCRIPTION FACTOR FOXP3;

ARTICLE; CD4+ CD25+ T LYMPHOCYTE; CELL CYCLE ARREST; CELL CYCLE G0 PHASE; CELL CYCLE G1 PHASE; CELL FUNCTION; CELL PROLIFERATION; CONTROLLED STUDY; DOSE RESPONSE; DOWN REGULATION; HUMAN; PRIORITY JOURNAL; REGULATORY T LYMPHOCYTE;

ANALYSIS OF VARIANCE; ANTIGENS, CD; CD4-POSITIVE T-LYMPHOCYTES; CELL CYCLE; CELL PROLIFERATION; CELLS, CULTURED; DOSE-RESPONSE RELATIONSHIP, DRUG; FORKHEAD TRANSCRIPTION FACTORS; HUMANS; INTERFERON-GAMMA; INTERLEUKIN-2 RECEPTOR ALPHA SUBUNIT; INTERLEUKIN-4; PROTEIN KINASE INHIBITORS; PYRIMIDINES; RECEPTORS, TUMOR NECROSIS FACTOR; SIGNAL TRANSDUCTION; THIAZOLES;

EID: 58149094991     PISSN: 00071048     EISSN: 13652141     Source Type: Journal    
DOI: 10.1111/j.1365-2141.2008.07433.x     Document Type: Article

References (42)

1. Beyer, M., Kochanek, M., Darabi, K., Popov, A., Jensen, M., Endl, E., Knolle, P.A., Thomas, R.K., von Bergwelt-Baildon, M., Debey, S., Hallek, M. Schultze, J.L. (2005) Reduced frequencies and suppressive function of CD4+CD25hi regulatory T cells in patients with chronic lymphocytic leukemia after therapy with fludarabine. Blood, 106, 2018 2025.
2. Chen, J., Schmitt, A., Bunjes, D., Chen, B. Schmitt, M. (2007a) The receptor for hyaluronic acid-mediated motility induces specific CD8+ T cell response in healthy donors and patients with chronic myeloid leukemia after allogeneic stem cell transplantation. International Journal of Oncology, 30, 1119 1127.
3. Chen, J., Schmitt, A., Chen, B., Rojewski, M., Ringhoffer, M., von Harsdorf, S., Greiner, J., Guillaume, P., Döhner, H., Bunjes, D. Schmitt, M. (2007b) Imatinib impairs CD8+ T lymphocytes specifically directed against the leukemia-associated antigen RHAMM/CD168 in vitro. Cancer Immunology, Immunotherapy, 56, 849 861.
4. Chen, J., Schmitt, A., Giannopoulos, K., Chen, B., Rojewski, M., Döhner, H., Bunjes, D. Schmitt, M. (2007c) Imatinib impairs the proliferation and function of CD4+CD25+ regulatory T cells in a dose-dependent manner. International Journal of Oncology, 31, 1133 1139.
5. Cortes, J., Rousselot, P., Kim, D.W., Ritchi, E., Hamerschlak, N., Coutre, S., Hochhaus, A., Guilhot, F., Saglio, G., Apperley, J., Ottmann, O., Shah, N., Erben, P., Branford, S., Agarwal, P., Gollerkeri, A. Baccarani, M. (2007) Dasatinib induces complete hematologic and cytogenetic responses in patients with imatinib-resistant or -intolerant chronic myeloid leukemia in blast crisis. Blood, 109, 3207 3213.
6. Cwynarski, K., Laylor, R., Macchiarulo, E., Goldman, J., Lombardi, G., Melo, J.V. Dazzi, F. (2004) Imatinib inhibits the activation and proliferation of normal T lymphocytes in vitro. Leukemia, 18, 1332 1339.
7. Edinger, M., Hoffmann, P., Ermann, J., Drago, K., Fathman, C.G., Strober, S. Negrin, R.S. (2003) CD4+CD25+ regulatory T cells preserve graft-versus-tumor activity while inhibiting graft-versus-host disease after bone marrow transplantation. Nature Medicine, 9, 1144 1150.
8. + T cells specific for viral and leukemia-antigens. Experimental Hematology, 36, 1297 1308.
9. Fontenot, J.D., Gavi, M.A. Rudensky, A.Y. (2003) Foxp3 programs the development and function of CD4+CD25+ regulatory T cells. Nature Immunology, 4, 330 336.
10. Guilhot, F., Apperley, J., Kim, D.W., Bullorsky, E.O., Baccarani, M., Roboz, G.J., Amadori, S., de Souza, C.A., Lipton, J.H., Hochhaus, A., Heim, D., Larson, R.A., Branford, S., Muller, M.C., Agarwal, P., Gollerkeri, A. Talpaz, M. (2007) Dasatinib induces significant hematologic and cytogenetic responses in patients with imatinib-resistant or -intolerant chronic myeloid leukemia in accelerated phase. Blood, 109, 4143 4150.
11. von Herrath, M.G. Harrison, L.C. (2003) Antigen-induced regulatory T cells in autoimmunity. Nature reviews. Immunology, 3, 223 232.
12. Hipp, M.M., Hilf, N., Walter, S., Werth, D., Brauer, K.M., Radsak, M.P., Weinschenk, T., Singh-Jasuja, H. Brossart, P. (2008) Sorafenib but not sunitinib affects function of dendritic cells and induction of primary immune responses. Blood, 111, 5610 5620.
13. Hochhaus, A., Kantarjian, H.M., Baccarani, M., Lipton, J.H., Apperley, J.F., Druker, B.J., Facon, T., Goldberg, S.L., Cervantes, F., Niederwieser, D., Silver, R.T., Stone, R.M., Hughes, T.P., Muller, M.C., Ezzeddine, R., Countouriotis, A.M. Shah, N.P. (2007) Dasatinib induces notable hematologic and cytogenetic responses in chronic-phase chronic myeloid leukemia after failure of imatinib therapy. Blood, 109, 2303 2309.
14. Hoffmann, P., Eder, R., Kunz-Schughart, L.A., Andreesen, R. Edinger, M. (2004) Large-scale in vitro expansion of polyclonal human CD4(+)CD25high regulatory T cells. Blood, 104, 895 903.
15. Johnson, F.M., Saigal, B., Talpaz, M. Donato, N.J. (2005) Dasatinib (BMS-354825) tyrosine kinase inhibitor suppresses invasion and induces cell cycle arrest and apoptosis of head and neck squamous cell carcinoma and non-small cell lung cancer cells. Clinical Cancer Research, 11, 6924 6932.
16. Kantarjian, H.M., Talpaz, M., Giles, F., O'Brien, S. Cortes, J. (2006) New insights into the pathophysiology of chronic myeloid leukemia and imatinib resistance. Annals of Internal Medicine, 145, 913 923.
17. Li, L., Godfrey, W.R., Porter, S.B., Ge, Y., June, C.H., Blazar, B.R. Boussiotis, V.A. (2005) CD4+CD25+ regulatory T-cell lines from human cord blood have functional and molecular properties of T-cell anergy. Blood, 106, 3068 3073.
18. Lombardo, L.J., Lee, F.Y., Chen, P., Norris, D., Barrish, J.C., Behnia, K., Castaneda, S., Cornelius, L.A., Das, J., Doweyko, A.M., Fairchild, C., Hunt, J.T., Inigo, I., Johnston, K., Kamath, A., Kan, D., Klei, H., Marathe, P., Pang, S., Peterson, R., Pitt, S., Schieven, G.L., Schmidt, R.J., Tokarski, J., Wen, M.L., Wityak, J. Borzilleri, R.M. (2004) Discovery of N-(2-chloro-6-methyl- phenyl)-2-(6- (4-(2-hydroxyethyl)-piperzin-1-yl)-2-methylpyrimidin-4-ylamino) thiazole-5-carboxamide(BMS-54825), a dual Src/Abl kinase inhibitor with potent anti-tumor activity in preclinical assays. Journal of Medicinal Chemistry, 47, 6658 6661.
19. Löwenberg, M., Tuynman, J., Bilderbeek, J., Gaber, T., Buttgereit, F., van Deventer, S., Peppelenbosch, M. Hommes, D. (2005) Rapid immunosuppressive effects of glucocorticoids mediated through Lck and Fyn. Blood, 106, 1703 1710.
20. Lutsiak, M.E., Semnani, R.T., De Pascalis, R., Kashmiri, S.V., Schlom, J. Sabzevari, H. (2005) Inhibition of CD4(+)CD25+ T regulatory cell function implicated in enhanced immune response by low-dose cyclophosphamide. Blood, 105, 2862 2868.
21. Martinelli, G., Soverini, S., Rosti, G. Baccarani, M. (2005) Dual tyrosine kinase inhibitors in chronic myeloid leukemia. Leukemia, 19, 1872 1879.
22. Nishikawa, H., Tsuji, T., Jäger, E., Briones, G., Ritter, G., Old, L.J., Galán, J.E., Shiku, H. Gnjatic, S. (2008) Induction of regulatory T cell-resistant helper CD4+ T cells by bacterial vector. Blood, 111, 1404 1412.
23. O'Hare, T., Walters, D.K., Stoffregen, E.P., Sherbenou, D.W., Heinrich, M.C., Deininger, M.W. Druker, B.J. (2005) Combined Abl inhibitor therapy for minimizing drug resistance in chronic myeloid leukemia: Src/Abl inhibitors are compatible with imatinib. Clinical Cancer Research, 11, 6987 6993.
24. O'Hare, T., Walter, D.K., Stoffregen, E.P., Jia, T., Manley, P.W., Mestan, J., Cowan-Jacob, S.W., Lee, F.Y., Heinrich, M.C., Deininger, M.W. Druker, B.J. (2006) In vitro activity of Bcr-Abl inhibitors AMN107 and BMS-354825 against clinically relevant Imatinib-resistant Abl kinase domain mutants. Cancer Research, 65, 4500 4505.
25. Ottmann, O., Dombret, H., Martinelli, G., Simonsson, B., Guilhot, F., Larson, R.A., Rege-Cambrin, G., Radich, J., Hochhaus, A., Apanovitch, A.M., Gollerkeri, A. Coutre, S. (2007) Dasatinib induces rapid hematologic and cytogenetic responses in adult patients with Philadelphia chromosome positive acute lymphoblastic leukemia with resistance or intolerance to imatinib: interim results of a phase 2 study. Blood, 110, 2309 2315.
26. Palacios, E.H. Weiss, A. (2004) Function of the Src-family kinases, Lck and Fyn, in T-cell development and activation. Oncogene, 23, 7990 8000.
27. Quintas-Cardama, A., Kantarjian, H., Jones, D., Nicaise, C., O'Brien, S., Giles, F., Talpaz, M. Cortes, J. (2007) Dasatinib (BMS-354825) is active in Philadelphia chromosome-positive chronic myelogenous leukemia after imatinib and nilotinib (AMN107) therapy failure. Blood, 109, 497 499.
28. Sakaguchi, S. (2004) Naturally arising CD4+ regulatory T cells for immunologic self-tolerance and negative control of immune responses. Annual review of Immunology, 22, 531 562.
29. Sakaguchi, S., Sakaguchi, N., Asano, M., Itoh, M. Toda, M. (1995) Immunologic self-tolerance maintained by activated T cells expressing IL-2 receptor alpha-chains (CD25). Breakdown of a single mechanism of self-tolerance causes various autoimmune diseases. Journal of Immunology, 155, 1151 1164.
30. Sakaguchi, S., Toda, M., Asano, M., Itoh, M., Morse, S.S. Sakaguchi, N. (1996) T cell-mediated maintenance of natural self-tolerance: its breakdown as a possible cause of various autoimmune diseases. Journal of Autoimmunity, 9, 211 220.
31. Sakaguchi, S., Sakaguchi, N., Shimizu, J., Yamazaki, S., Sakihama, T., Itoh, M., Kuniyasu, Y., Nomura, T., Toda, M. Takahashi, T. (2001) Immunologic tolerance maintained by CD25+ CD4+ regulatory T cells: their common role in controlling autoimmunity, tumor immunity, and transplantation tolerance. Immunological reviews, 182, 18 32.
32. Sansom, D.M. Walker, L.S. (2006) The role of CD28 and cytotoxic T-lymphocyte antigen-4 (CTLA-4) in regulatory T-cell biology. Immunological reviews, 212, 131 148.
33. Schade, A.E., Schieven, G.L., Townsend, R., Jankowska, A.M., Susulic, V., Zhang, R., Szpurka, H. Maciejewski, J.P. (2008) Dasatinib, a small molecule protein tyrosine kinase inhibitor, inhibits T cell activation and proliferation. Blood, 111, 1366 1377.
34. Shevach, E.M. (2002) CD4+ CD25+ suppressor T cells: more questions than answers. Nature reviews. Immunology, 2, 389 400.
35. Strauss, L., Whiteside, T.L., Knights, A., Bergmann, C., Knuth, A. Zippelius, A. (2007) Selective survival of naturally occurring human CD4+CD25+Foxp3+ regulatory T cells cultured with rapamycin. Journal of Immunology, 178, 320 329.
36. Talpaz, M., Shah, N.P., Kantarjian, H., Donato, N., Nicoll, J., Paquette, R., Cortes, J., O'Brien, S., Nicaise, C., Bleickardt, E., Blackwood-Chirchir, M.A., Iyer, V., Chen, T.T., Huang, F., Decillis, A.P. Sawyers, C.L. (2006) Dasatinib in imatinib-resistant Philadelphia chromosome-positive leukemias. New England Journal of Medicine, 354, 2531 2541.
37. Tokarski, J.S., Newitt, J.A., Chang, C.Y., Cheng, J.D., Wittekind, M., Kiefer, S.E., Kish, K., Lee, F.Y., Borzillerri, R., Lombardo, L.J., Xie, D., Zhang, Y. Klei, H.E. (2006) The structure of Dasatinib (BMS-354825) bound to activated ABL kinase domain elucidates its inhibitory activity against imatinib-resistant ABL mutants. Cancer Research, 66, 5790 5797.
38. Walker, M.R., Kasprowicz, D.J., Gersuk, V.H., Benard, A., Van Landeghen, M., Buckner, J.H. Ziegler, S.F. (2003) Induction of FoxP3 and acquisition of T regulatory activity by stimulated human CD4+CD25- T cells. Journal of Clinical Investigation, 112, 1437 1443.
39. Weichsel, R., Dix, C., Wooldridge, L., Clement., M., Fenton-May, A., Sewell, A.K., Zezula, J., Greiner, E., Gostick, E., Price, D.A., Einsele, H. Seggewiss, R. (2008) Profound inhibition of antigen-specific T-cell effector functions by dasatinib. Clinical Cancer Research, 14, 2484 2491.
40. Weil, R. Israel, A. (2006) Deciphering the pathway from the TCR to NF-kappaB. Cell Death and Differentiation, 13, 826 833.
41. Weisberg, E., Manley, P.W., Cowan-Jacob, S.W., Hochhaus, A. Griffin, J.D. (2007) Second generation inhibitors of BCR-ABL for the treatment of imatinib-resistant chronic myeloid leukaemia. Nature reviews. Cancer, 7, 345 356.
42. Zeiser, R., Nguyen, V.H., Beilhack, A., Buess, M., Schul, S., Baker, J., Contag, C.H. Negrin, R.S. (2006) Inhibition of CD4+CD25+ regulatory T-cell function by calcineurin-dependent interleukin-2 production. Blood, 108, 390 399.